Transdel Reports Positive Phase 3 Results For Ketotransdel
Transdel Pharmaceuticals (Transdel) has reported positive top-line clinical results for its lead pain drug, Ketotransdel, in a phase 3 trial. The study evaluated the efficacy and safety of
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.